748 completed. 748 Phase 2, 177 Phase 1, 11 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 748 | Completed 748 |
| Phase 1 | 177 | Completed 177 |
| Phase 3 | 11 | Completed 11 |
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant GPC-100, Propranolol, G-CSF - Multiple Myeloma | Phase 2 | Completed | GPCR Therapeutics, Inc. | 30 | 2023-02-13 | 2026-02-12 |
| SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease Selinexor, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 2 | Completed | The First Affiliated Hospital with Nanjing Medical University | 29 | 2022-07-15 | 2026-09-02 |
| Phase I Trial of GR1803 Injection in Patients With RRMM GR1803 injection - Multiple Myeloma (MM) | Phase 1 / Phase 2 | Completed | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 76 | 2022-05-27 | 2025-08-05 |
| A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma Cilta-cel, Lymphodepleting Therapy (Cyclophosphamide and Fludarabine) - Multiple Myeloma | Phase 2 | Completed | Janssen Scientific Affairs, LLC | 86 | 2022-05-13 | 2025-04-25 |
| Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant Pegfilgrastim - Myeloma Multiple, Lymphoma | Phase 2 | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2022-04-01 | 2023-02-28 |
| Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma Belantamab mafodotin - Multiple Myeloma | Phase 2 | Completed | GlaxoSmithKline | 177 | 2022-03-03 | 2026-05-05 |
| Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma Lenalidomide, bb2121, Cyclophosphamide - Multiple Myeloma | Phase 2 | Completed | Medical College of Wisconsin | 40 | 2022-01-05 | 2026-05-19 |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. Elranatamab - Elranatamab, Myeloma | Phase 2 | Completed | Pfizer | 39 | 2021-12-21 | 2026-09-29 |
| Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer Curcumin plus Piperine - Prostate Cancer, Multiple Myeloma | Phase 2 | Completed | University of Rochester | 30 | 2021-12-14 | 2026-05-12 |
| Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Siltuximab - Cytokine Release Syndrome, ICANS | Phase 2 | Completed | University of Alabama at Birmingham | 20 | 2021-11-15 | 2026-07-27 |
| A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment Elranatamab - Multiple Myeloma | Phase 2 | Completed | Pfizer | 86 | 2021-10-07 | 2026-02-10 |
| A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma KRN125(pegfilgrastim), PLR001(plerixafor), KRN8601(filgrastim), PLR001(plerixafor) - Multiple Myeloma and Malignant Lymphoma | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 64 | 2021-09-01 | 2023-02-21 |
| COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies A single "booster" dose of the Moderna mRNA COVID-19 vaccine - Multiple Myeloma, AL Amyloidosis | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 119 | 2021-08-17 | 2023-12-20 |
| REST - Replacing Steroids in the Transplant Ineligble Isatuximab, bortezomib, lenalidomide, dexamethason - Multiple Myeloma | Phase 2 | Completed | Oslo University Hospital | 51 | 2021-06-29 | 2025-03-20 |
| Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) Uproleselan, Placebo, Melphalan - Multiple Myeloma | Phase 2 | Completed | Washington University School of Medicine | 51 | 2021-05-05 | 2023-12-15 |
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG - Solid Tumor Malignancy, Hematologic Malignancy | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2021-04-28 | 2024-08-27 |
| Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Descartes 11 - Multiple Myeloma | Phase 2 | Completed | Cartesian Therapeutics | 5 | 2021-02-24 | 2024-12-03 |
| MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb Elranatamab (PF-06863135) - Multiple Myeloma | Phase 2 | Completed | Pfizer | 187 | 2021-02-02 | 2026-10-19 |
| RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma RAPA-201 Autologous T cells - Relapsed, Refractory Multiple Myeloma | Phase 2 | Completed | Rapa Therapeutics LLC | 15 | 2020-12-02 | 2025-05-15 |
| Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma AO-176, AO-176 + Dex, AO-176 + Dex + Bort - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Arch Oncology | 10 | 2020-11-30 | 2023-08-22 |
Showing 20 of 748. Sign in to see all of them.
Neoplasms, Plasma Cell (176) · Lymphoma, Non-Hodgkin (134) · Hodgkin Disease (122) · Leukemia, Lymphocytic, Chronic, B-Cell (112) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (103) · Lymphoma (96) · Leukemia, Myeloid, Acute (94) · Recurrence (94) · Leukemia (88) · Myelodysplastic Syndromes (82) · Lymphoma, Follicular (81) · Lymphoma, Mantle-Cell (78) · Lymphoma, B-Cell, Marginal Zone (76) · Burkitt Lymphoma (73)
Hemic and Lymphatic Diseases (748) · Cardiovascular Diseases (746) · Neoplasms by Histologic Type (746) · Vascular Diseases (746) · Hemorrhagic Disorders (745) · Hemostatic Disorders (745) · Immune System Diseases (745) · Immunoproliferative Disorders (745) · Blood Protein Disorders (744) · Lymphoproliferative Disorders (740) · Paraproteinemias (740) · Hematologic Diseases (738) · Neoplasms (727) · Neoplasms, Plasma Cell (572) · Pathological Conditions, Signs and Symptoms (195)
Dexamethasone (211) · Bortezomib (124) · Cyclophosphamide (123) · Lenalidomide (123) · Melphalan (107) · Calcium Dobesilate (66) · Peripheral Blood Stem Cell Transplantation (64) · fludarabine phosphate (56) · Filgrastim (45) · Mycophenolic Acid (45) · Thalidomide (44) · Busulfan (42) · Granulocyte Colony-Stimulating Factor (40) · carfilzomib (40) · Whole-Body Irradiation (38)
Fred Hutchinson Cancer Center (42) · Mayo Clinic (39) · National Cancer Institute (NCI) (28) · Memorial Sloan Kettering Cancer Center (23) · M.D. Anderson Cancer Center (22) · University of Arkansas (17) · Celgene (16) · H. Lee Moffitt Cancer Center and Research Institute (15) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (14) · Amgen (12) · Janssen Research & Development, LLC (11) · University of Michigan Rogel Cancer Center (10) · Novartis Pharmaceuticals (9) · Bristol-Myers Squibb (8) · Case Comprehensive Cancer Center (8)
United States (538) · Germany (59) · Canada (56) · France (55) · Italy (53) · Spain (46) · United Kingdom (34) · Greece (25) · Australia (23) · Netherlands (23) · Belgium (19) · Japan (19) · Denmark (18) · Austria (17) · Poland (15)
Brenda Sandmaier (9) · Shaji Kumar (6) · William I. Bensinger, MD (6) · Ivan Borrello, MD (5) · Leona Holmberg (5) · Muzaffar H. Qazilbash, MD (5) · Paul Richardson, MD (5)
PMID 32499241, PMID 35549810, PMID 31221778, PMID 40156952, PMID 20661232, PMID 25628469, PMID 26181891, PMID 26308596, PMID 26690712, PMID 27307294, PMID 29025767, PMID 30536810, PMID 30957581, PMID 32107329, PMID 32470437, PMID 34465265, PMID 35132679, PMID 37022569, PMID 37934000, PMID 38649340, PMID 40000533, PMID 40471585, PMID 40826257, PMID 42287565, PMID 10084252, PMID 10414913, PMID 10414914, PMID 10459351, PMID 10482933, PMID 10564685, PMID 10918404, PMID 12000194, PMID 12473574, PMID 14508361, PMID 14767498, PMID 15156165, PMID 15241836, PMID 15308571, PMID 15623591, PMID 15867202, PMID 15880129, PMID 15902208, PMID 15911237, PMID 15958804, PMID 16398649, PMID 17947482, PMID 17975015, PMID 17989313, PMID 18032762, PMID 18032763
P30CA015083 (26), P30CA015704 (19), 2017 (10), P30CA006973 (9), 2005 (7), 2008 (7), P01CA018029 (7), P01CA078902 (6), U10CA032102 (6), 2009 (5), 2014 (4), 2015 (4), 2016 (4), 2018 (4), P30CA033572 (4)